Volume 15, Issue 4 (Autumn 2024)
Caspian J Intern Med 2024, 15(4): 743-747 |
Back to browse issues page
Marcio Concepción-Zavaleta * 
, Guillermo Ramos-Torres , Juan Quiroz-Aldave , María Durand-Vásquez , Sofía Ildefonso-Najarro , Elena De Jesús Alvarado-León , Francisca Zavaleta-Gutiérrez , Luis Concepción-Urteaga , José Paz-Ibarra
, Guillermo Ramos-Torres , Juan Quiroz-Aldave , María Durand-Vásquez , Sofía Ildefonso-Najarro , Elena De Jesús Alvarado-León , Francisca Zavaleta-Gutiérrez , Luis Concepción-Urteaga , José Paz-Ibarra
Universidad Científica del sur, Lima, Perú , marcio_conc_zav@outlook.es
Abstract: (1076 Views)
Background: Ifosfamide-induced Fanconi syndrome is a relatively infrequent complication that generally occurs in young patients with a high cumulative dose of ifosfamide; and is commonly characterized by glycosuria, proteinuria, electrolyte abnormalities, and a normal anion gap metabolic acidosis.
Case Presentation: In this study, we present the case of a 16-year-old male patient with of osteosarcoma of the right femur with pulmonary metastasis, who received ifosfamide as part of chemotherapy 1 year and 2 months ago and required hospitalization for cellulitis. During inpatient management, he presented with hypokalemia, hypophosphatemia, polyuria, glycosuria, and proteinuria, by which he was diagnosed with Fanconi syndrome and nephrogenic diabetes insipidus, induced by ifosfamide. Management was focused on the control of the internal environment and use of potassium supplements and potassium-sparing diuretics.
Conclusion: Patients receiving ifosfamide should be periodically monitored for kidney function and internal environment to detect any potential complications. It is thus important to carefully observe the cumulative dose of ifosfamide to prevent its associated nephrotoxicity, since its appearance can impoverish the prognosis in patients with neoplasms. Therefore, physicians should always be aware about the possibility of nephrotoxicity development.
Case Presentation: In this study, we present the case of a 16-year-old male patient with of osteosarcoma of the right femur with pulmonary metastasis, who received ifosfamide as part of chemotherapy 1 year and 2 months ago and required hospitalization for cellulitis. During inpatient management, he presented with hypokalemia, hypophosphatemia, polyuria, glycosuria, and proteinuria, by which he was diagnosed with Fanconi syndrome and nephrogenic diabetes insipidus, induced by ifosfamide. Management was focused on the control of the internal environment and use of potassium supplements and potassium-sparing diuretics.
Conclusion: Patients receiving ifosfamide should be periodically monitored for kidney function and internal environment to detect any potential complications. It is thus important to carefully observe the cumulative dose of ifosfamide to prevent its associated nephrotoxicity, since its appearance can impoverish the prognosis in patients with neoplasms. Therefore, physicians should always be aware about the possibility of nephrotoxicity development.
Type of Study: case report |
Subject:
Nephrology
Received: 2022/09/26 | Accepted: 2024/08/28 | Published: 2024/08/28
Received: 2022/09/26 | Accepted: 2024/08/28 | Published: 2024/08/28
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |